# Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

> **NCT00157950** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 176 (actual)

## Conditions studied

- Papillomavirus Infections

## Interventions

- **BIOLOGICAL:** Gardasil™
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00157950
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00157950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00157950, "Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00157950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*